<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655315</url>
  </required_header>
  <id_info>
    <org_study_id>2015_22</org_study_id>
    <secondary_id>2015-003679-31</secondary_id>
    <secondary_id>Grant agreement No 633190</secondary_id>
    <secondary_id>HP751</secondary_id>
    <nct_id>NCT02655315</nct_id>
  </id_info>
  <brief_title>Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease</brief_title>
  <acronym>FAIRPARKII</acronym>
  <official_title>Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of iron chelation as a therapeutic strategy to slow the&#xD;
      progression of Parkinson's disease. Half of participants will receive the deferiprone to 15&#xD;
      mg / kg twice daily morning and evening (30mg / kg per day), while the other half will&#xD;
      receive a placebo. The treatment lasts nine months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the new concept of &quot;conservative iron chelation&quot;. We recently demonstrated (for the&#xD;
      first time) the feasibility, efficacy and acceptability of the conservative iron chelation&#xD;
      approach in pilot translational studies in Parkinson's disease with a prototype drug:&#xD;
      deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (in the FAIR-PARK-I project led by the&#xD;
      applicant and funded by French Ministry of Health). The only available&#xD;
      blood-brain-barrier-permeable iron chelator deferiprone is approved for treating systemic&#xD;
      iron overload in transfused patients with thalassemia. Deferiprone has been on the European&#xD;
      Union market since 1999, with a favourable risk/benefit balance at dose of 75 to 100&#xD;
      mg/kg/day. The investigators shall adopt a repositioning strategy by using deferiprone at a&#xD;
      lower dose of 30 mg/kg/day in this new indication for local iron overload in Parkinson's&#xD;
      disease. Deferiprone will be the first-in-class drug for this novel therapeutic strategy. On&#xD;
      the basis of the preclinical and clinical data from (FAIR-PARK-I), the present (FAIR-PARK-II)&#xD;
      project should constitute a model for future cytoprotection strategies in neurodegenerative&#xD;
      diseases; if deferiprone treatment is associated with significant slower disease progression,&#xD;
      it would be the first non-dopaminergic drug to have a proven disease-modifying effect in&#xD;
      Parkinson's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global effect (symptomatic and disease modifying effects) on motor and non motor handicap</measure>
    <time_frame>at 36 weeks</time_frame>
    <description>the change in the total Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease-modifying and symptomatic effects)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-modifying effect on motor and non motor handicap</measure>
    <time_frame>baseline, at 40 weeks</time_frame>
    <description>It will be measured as the changes in the overall Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and week 40 (i.e. the end of the one-month post-treatment monitoring period), to analyse the disease-modifying effect without bias from the symptomatic effect of ongoing deferiprone treatment) on the study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the motor symptoms</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>The effect of the motor symptoms will be analysed as the change in the subscale part III of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and autonomy by PDQ-39 score</measure>
    <time_frame>baseline, at 36 and 40 weeks</time_frame>
    <description>It will be analyzed as the change in the Parkinson's Disease Quality of Life (PDQ-39, via a 39-item self-questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and autonomy by Clinical Global Impression score</measure>
    <time_frame>baseline, at 36 and 40 weeks</time_frame>
    <description>the Clinical Global Impression scored by the examiner and the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics assessment</measure>
    <time_frame>baseline, at 36 and 40 weeks</time_frame>
    <description>will be performed via a specific questionnaire provides a simple descriptive profile and a single index value for health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D questionnaire</measure>
    <time_frame>baseline, at 36 and 40 weeks</time_frame>
    <description>the questionnaire provides a simple descriptive profile and a single index value for health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety criteria</measure>
    <time_frame>40 weeks</time_frame>
    <description>All the safety concerns will be listed in a table with the number of patients, the type the severity and the time of occurrence for&#xD;
adverse events&#xD;
neutropenia (weekly complete blood count)&#xD;
agranulocytosis (weekly complete blood count)&#xD;
anemia (weekly complete blood count)&#xD;
iron metabolism abnormalities (haemoglobin, serum iron, ferritinemia, transferrin, total binding capacity, transferrin saturation coefficient, 24-hour urine iron).&#xD;
Standard biological abnormalities (fasting glucose, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and (for all sexually active, fertile females) urine pregnancy tests.&#xD;
Abnormal physical examination (including vital signs, bodyweight, electrocardiogram and blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on overall cognitive status</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>Measured by the score in the Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on gait disorders</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>Measured by the Stand Walk Sit test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on daily living</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>The effect on daily living will be analysed as the change in the subscale part II (activities of daily living) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on non-motor symptoms</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>The effect on non motor symptoms will be analysed as the change in the subscale part I (cognition and behavior) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lack of occurrence of motor fluctuations</measure>
    <time_frame>baseline, at 12, 36 and 40 weeks</time_frame>
    <description>The lack of occurrence of motor fluctuations will be analysed on the subscale part IV of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>DEFERIPRONE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.</description>
    <arm_group_label>DEFERIPRONE</arm_group_label>
    <other_name>active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the placebo twice daily morning and evening. The treatment lasts nine months</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>harmless pill</other_name>
    <other_name>inactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients&#xD;
&#xD;
          2. Parkinson's disease diagnosed according United Kingdom Parkinson's disease Society&#xD;
             Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of&#xD;
             the three cardinal features of the disease (rest tremor, bradykinesia and rigidity).&#xD;
             If rest tremor is not present, subjects must have unilateral onset of symptoms.&#xD;
&#xD;
          3. Treatment-naïve, i.e. the best population for assessing a disease-modifying effect&#xD;
             without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa,&#xD;
             anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain&#xD;
             stimulation).&#xD;
&#xD;
          4. Patients covered by a Health Insurance System in countries where required by law&#xD;
&#xD;
          5. Written informed consent dated and signed prior to the beginning of any procedures&#xD;
             related to the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Disease duration greater than 18 months.&#xD;
&#xD;
          2. Patients with high frequency of comorbidity or vital risks that may reasonably impair&#xD;
             life expectancy&#xD;
&#xD;
          3. Subject with handicap required dopaminergic treatment at the inclusion and therefore&#xD;
             likely not to bear 9 months without symptomatic treatment&#xD;
&#xD;
          4. Hoehn and Yahr stage 3 or more.&#xD;
&#xD;
          5. Significant cognitive impairment (a Mini Mental State Examination score &lt;24 or an&#xD;
             equivalent impairment on a similar scale) or dementia diagnosed in accordance with the&#xD;
             Movement Disorders Society criteria (Emre et al., 2007).&#xD;
&#xD;
          6. Atypical or secondary parkinsonism (supranuclear palsy, multisystem atrophy, etc.) or&#xD;
             anomalies on MRI suggestive of vascular involvement or significant cortical or&#xD;
             subcortical atrophy (i.e. atypical for Parkinson's Disease).&#xD;
&#xD;
          7. Progressing axis I psychiatric disorders (psychosis, hallucinations, substance&#xD;
             addiction, bipolar disorder, or severe depression), in accordance with the Diagnostic&#xD;
             and Statistical Manual of Mental Disorders.&#xD;
&#xD;
          8. Subjects undergoing brain stimulation.&#xD;
&#xD;
          9. Positive Human Immunodepression Virus serology.&#xD;
&#xD;
         10. Hypersensitivity to deferiprone.&#xD;
&#xD;
         11. Patients with agranulocytosis or with a history of agranulocytosis.&#xD;
&#xD;
         12. Patients taking a treatment at risk of agranulocytosis (clozapine,&#xD;
             Closaril®/Leponex®).&#xD;
&#xD;
         13. Patients with anaemia (regardless of the latter's aetiology) or a history of another&#xD;
             haematological disease. Haemochromatosis is not an exclusion criterion.&#xD;
&#xD;
         14. Pregnant or breastfeeding women or women of childbearing potential not taking highly&#xD;
             effective contraception.&#xD;
&#xD;
         15. Kidney or liver failure.&#xD;
&#xD;
         16. Other serious diseases.&#xD;
&#xD;
         17. Inability to provide informed consent.&#xD;
&#xD;
         18. Participation in another clinical trial with investigational medicinal product within&#xD;
             3 months prior to inclusion in the study&#xD;
&#xD;
         19. Patient who has suffered mild or moderate depressive episode and isn't in remission&#xD;
             and on a stable medication for at least 8 weeks&#xD;
&#xD;
         20. Patient &gt; 130k&#xD;
&#xD;
        Exclusion criteria for the biomarker study and the ancillary study (i) Magnetic Resonance&#xD;
        Imaging:&#xD;
&#xD;
          -  Subjects for whom Magnetic Resonance Imaging is contraindicated (metal objects in the&#xD;
             body, severe claustrophobia, pacemaker, incompatible surgical material).&#xD;
&#xD;
          -  Very severe rest tremor, which could induce Magnetic Resonance Imaging artefacts.&#xD;
&#xD;
        (ii) Lumbar puncture:&#xD;
&#xD;
          -  Blood coagulation disorders, antiplatelet drugs or anticoagulants.&#xD;
&#xD;
          -  Intracranial hypertension. (iii) Contraindications to nitrous oxide:&#xD;
&#xD;
          -  Ventilation with Fraction of inspired Oxygen &gt;50%, emphysema or pneumothorax&#xD;
&#xD;
          -  Altered states of consciousness, non-cooperative patient (need to stop the nitrous&#xD;
             oxide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Devos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzita Karlova V Praze</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Salengro, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU la TIMONE</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg, Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Saarland University</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian-albrechts universität zu kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acadamic central center, Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e universitario de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Alto Ave</name>
      <address>
        <city>Guimarães</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universitari de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://fairpark2.eu/</url>
    <description>Website for informations on the Fairpark2 study</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>Chelation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

